Merck v. Merck Facebook fracas a "tempest in a teapot" says US firm

Share this article:
Merck v. Merck Facebook fracas a "tempest in a teapot" says US firm
Merck v. Merck Facebook fracas a "tempest in a teapot" says US firm
Facebook shut down Facebook.com/Merck after Merck KGaA announced plans to take legal action “based on the apparent takeover of its Facebook page” by its US cousin, Merck & Co.

The social media behemoth, which unwrapped plans for an initial public offering today, essentially told the two companies to work it out, calling its assignment of the URL to the US firm "an administrative error."

“We have removed the vanity URL,” said Facebook's Andrew Noyes, manager, public policy communications. “Facebook.com/Merck will be unavailable unless and until the two companies mutually agree that one can use it.” Either company, he added, is welcome to create a new username or vanity URL for themselves.

The fracas over the Facebook address is nothing but a “tempest in a teapot,” a spokesman for Merck & Co. said, noting that it hasn't affected the company's Facebook presence since the so-called “vanity URL” simply redirected to the US-based drug maker's page, which remains live (as does the German Merck's. Moreover, it's a non-issue, he added, since most people find the page through search rather than typing in a URL. In fact, the publicity has netted Merck & Co. “hundreds” of new followers over the past few days. Merck & Co. is considering all options with regards to the vanity URL, he said.

At issue is a pre-action disclosure filed with the New York Supreme Court and dated Nov. 21, stating that the “misappropriation” of the URL by “a similarly-named and unrelated competitor” is “causing harm” to the German firm.

A Merck KGaA spokesman said “All I can tell you is we are looking into the matter.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...